Syros To Discontinue Enrollment In SELECT-AML-1 Phase 2 Clinical Trial; Says Disappointed By The Unexpected Outcome
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial due to disappointing interim results. The trial was evaluating a triplet regimen of tamibarotene with venetoclax and azacitidine compared to a doublet regimen in AML patients. The decision follows a futility analysis showing similar response rates between the two treatment arms.
August 12, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Syros Pharmaceuticals has decided to discontinue enrollment in its SELECT-AML-1 Phase 2 clinical trial due to disappointing interim results. The trial showed similar response rates between the triplet and doublet treatment arms, leading to a low probability of demonstrating superiority in the final analysis.
The discontinuation of the SELECT-AML-1 trial is a significant setback for Syros Pharmaceuticals, as it indicates that the triplet regimen did not show a superior response rate compared to the doublet regimen. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100